Orchestra BioMed Holdings (OBIO) Other Operating Expenses (2022 - 2026)
Orchestra BioMed Holdings (OBIO) posted quarterly Other Operating Expenses of $1.4 million for Q1 2026, up 734.34% year-over-year from $166000.0 in Q1 2025, and up 372.1% quarter-over-quarter from -$509000.0 in Q4 2025.
Powered by 
Analysis
Orchestra BioMed Holdings (OBIO) Other Operating Expenses (2022 - 2026) Analysis & Trends
Orchestra BioMed Holdings (OBIO) has reported Other Operating Expenses for 5 consecutive years, with $1.4 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Other Operating Expenses rose 734.34% year-over-year to $1.4 million; the TTM figure through Mar 2026 stood at $325000.0 (down 86.91% YoY), while the FY2025 annual figure was -$894000.0, down 127.28% from the prior year.
- Other Operating Expenses climbed to $1.4 million in Q1 2026 per OBIO's latest filing, from -$509000.0 in the prior quarter.
- Across five years, Other Operating Expenses topped out at $1.4 million in Q1 2026 and bottomed at -$601000.0 in Q1 2022.
- Historically, Other Operating Expenses has averaged $306058.8 across 5 years, with a median of $166000.0 in 2025.
- Annual changes were most pronounced in 2023 — Other Operating Expenses tumbled 532.05% — and 2026, when it soared 734.34%.
- Orchestra BioMed Holdings' Other Operating Expenses stood at $78000.0 in 2022, then sank by 532.05% to -$337000.0 in 2023, then jumped by 254.9% to $522000.0 in 2024, then sank by 197.51% to -$509000.0 in 2025, then soared by 372.1% to $1.4 million in 2026.
- Business Quant data shows OBIO's Other Operating Expenses at $1.4 million in Q1 2026, -$509000.0 in Q4 2025, and -$515000.0 in Q3 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn |
| 10 | Orchestra BioMed Holdings | 322.25 Mn | 127.72 Mn | 63,000.00 |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -1.40 Mn |
| Mar 31, 2026 | 1.39 Mn |
| Dec 31, 2025 | -509,000.00 |
| Sep 30, 2025 | -515,000.00 |
| Jun 30, 2025 | -36,000.00 |
| Mar 31, 2025 | 166,000.00 |
| Dec 31, 2024 | 522,000.00 |
| Sep 30, 2024 | 916,000.00 |
| Jun 30, 2024 | 879,000.00 |
| Mar 31, 2024 | 960,000.00 |
| Dec 31, 2023 | -337,000.00 |
| Sep 30, 2023 | 1.21 Mn |
| Jun 30, 2023 | 910,000.00 |
| Mar 31, 2023 | 605,000.00 |
| Dec 31, 2022 | 78,000.00 |
| Sep 30, 2022 | -215,000.00 |
| Jun 30, 2022 | -213,000.00 |
| Mar 31, 2022 | -601,000.00 |